Trial · NCT07536373
Colchicine in Chronic Limb-Threatening Ischemia
NCT07536373, Phase 3, Recruiting, Shin Kong Wu Ho-Su Memorial Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Colchicine in Chronic Limb-Threatening Ischemia. Trials, record NCT07536373. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07536373
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Colchicine in Chronic Limb-Threatening Ischemia
- NCT number
- NCT07536373
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
- Conditions
- Chronic Limb-Threatening Ischemia
- Interventions
- Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
- First posted
- 2026-04-17
- Last updated
- 2026-07-14
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Amputation-free survival | 12 months | Defined as the time to major (above the ankle) amputation of the study limb or death from any cause |
| Secondary | Number of Participants with Major (Above the Ankle) Non-Traumatic Amputation of the Study Limb | 12 months | Number of participants who underwent major (above the ankle) non-traumatic amputation of the study limb during the 12-month follow-up period. |
| Secondary | Major adverse limb event (MALE, including non-traumatic above-ankle amputation and major lower limb artery reintervention) and its components | 12 months | |
| Secondary | Major adverse cardiovascular event (MACE, including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) and its components | 12 months | |
| Secondary | Wound healing rates at 3, 6, 9 and 12 months for Rutherford 5 patients (or time to wound healing) | 12 months | |
| Secondary | Number of Participants with Acute Limb Ischemia | 12 months | Number of participants experiencing acute limb ischemia of the study limb during the 12-month follow-up period, adjudicated by a blinded clinical events committee. |
| Secondary | Number of Deaths from Any Cause | 12 months | Number of participants who died from any cause during the 12-month follow-up period. |
| Secondary | Number of Deaths from Cardiovascular Causes | 12 months | Number of participants who died from cardiovascular causes during the 12-month follow-up period, adjudicated by a blinded clinical events committee. |
| Secondary | Number of Deaths from Limb-Related Causes | 12 months | Number of participants who died from limb-related causes (e.g., fatal limb sepsis, complications of major amputation) during the 12-month follow-up period. |
| Secondary | Number of Participants with Adverse Gastrointestinal Events | 12 months | Number of participants experiencing adverse gastrointestinal events (including nausea, vomiting, abdominal pain, and diarrhea) during the 12-month treatment period. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07536373
GET https://conductscience.org/api/trials/v1/NCT07536373/registered?page=2